You have just completed a fragment screen and titrated your hits for confirmation. You have 15 chemotypes you want to follow up on, so you set out to find 10 close analogs for each one. Since this is early days, you don’t want to commit to chemistry, so you search for available compounds. After a…

Are you unsure whether Fragment Based Drug Discovery is a valid approach for your target?
Fragment Based Drug Discovery is now a well-established method to develop small molecule therapeutics for challenging drug targets. Orthosteric inhibitors, allosteric inhibitors (Asciminib) and Molecular Glues (ImIDs) are just some of the mechanisms of action…

Are you developing or thinking of developing small molecule therapeutics against a really challenging target? If so, does one of these scenarios describe your situation?
– You are trying to determine which small molecule approach is best for your target (orthosteric/allosteric inhibitor, degrader…

LEIDEN, NL
ZoBio, a boutique problem-solving Contract Research Organization (CRO) specializing in early gene-to-lead discovery, today announced the launch of its comprehensive…